Novartis Ag (NVS) EBIT Margin (2009 - 2025)

Novartis Ag (NVS) has 15 years of EBIT Margin data on file, last reported at 125.82% in Q2 2025.

• Quarterly EBIT Margin rose 9374.0% year-over-year to 125.82% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 77.33% (down 1070147.0% YoY) and the FY2025 annual result came in at 32.36%, up 345.0% from the prior year.
• EBIT Margin grew to 125.82% in Q2 2025 per NVS's latest filing, from 120.96% in the prior quarter.
• The five-year high for EBIT Margin was 13229852.53% in Q1 2022, with the low at 393389.37% in Q4 2022.
• Average EBIT Margin over 5 years is 1057505.26%, with a median of 120.77% recorded in 2022.
• Year-over-year, EBIT Margin surged 1322959274 bps in 2022 and sank 1168640778 bps in 2023.
• Novartis Ag's EBIT Margin stood at 3.24% in 2021, then sank by 12140134 bps to 393389.37% in 2022, then surged by 100 bps to 24.4% in 2023, then jumped by 396 bps to 120.96% in 2024, then grew by 4 bps to 125.82% in 2025.
• Business Quant data shows NVS's EBIT Margin at 125.82% in Q2 2025, 120.96% in Q4 2024, and 32.08% in Q2 2024.